Assessment of comorbidities in patients with deranged thyroid hormone levels


  • Sneha D. Narwade Department of Pharmacology, B. J. Government Medical College, Pune, Maharashtra, India
  • Rohidas M. Barve Department of Pharmacology, B. J. Government Medical College, Pune, Maharashtra, India



Hypothyroidism, Hyperthyroidism, Diabetes mellitus, Comorbidity, Drug interactions


Background: There is association of deranged thyroid hormone levels with various co-morbidities. Drugs for comorbidity may interact with each other and affect the outcome of treatment. So, this study was planned to find out comorbidities with deranged thyroid hormone levels and various possible drug interactions.

Methods: It was a prospective, observational study carried out at tertiary care hospital from November 2017 to June 2018. Thyroid hormonal levels reports were followed in OPD and online information system facility. Drugs interactions were checked by referring standard pharmacology textbooks, review articles and Medscape drug interaction checker. Approval from the Institutional Ethics Committee was taken before initiation of the study. Patients with deranged thyroid hormone levels were included in the study.

Results: Study was conducted in 111 patients of thyroid disorders. Spondylitis, asthma, acne cases were seen in hypothyroid patients whereas hypokalemic periodic paralysis, thyroid ophthalmopathy statistically significantly seen in hyperthyroid patients. Various concurrent medications such as calcium, carbamazepine decreases the effects of levothyroxine. For management of comorbidities various drugs are given which also interact among themselves significantly.

Conclusions: Diabetes mellites, obesity, spondylitis, lichen planus were more common in hypothyroidism while comorbidities like hypertension, hypokalemic periodic paralysis, thyroid ophthalmopathy were found to be more in hyperthyroidism.  Incidence of drug interactions is found to be more with increased use of medications for comorbidities, so physicians should be careful while prescribing them. Due to drug interactions desired effects of drugs given for thyroid disorders may not be observed.

Author Biographies

Sneha D. Narwade, Department of Pharmacology, B. J. Government Medical College, Pune, Maharashtra, India


Rohidas M. Barve, Department of Pharmacology, B. J. Government Medical College, Pune, Maharashtra, India



Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison’s Principles of Internal Medicine,19th ed. New York: McGraw Hill; 2015.

Velayutham K, Selvan S, Unnikrishnan AG. Prevalence of thyroid dysfunction among young females in a South Indian population. Indian Journal of Endocrinology and Metabolism. 2015;19(6):781-4.

Chandel K, Singh RB, Kumar S, Gupta A, Nath K. Evaluation of Thyroid Hormone dysfunction in patients of Type-2 Diabetes mellitus. Indian J Clin Anatomy Physiology. 2016;3(1):21-3.

McMillan M, Rotenberg KS, Vora K, Sterman A. Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance. Project. 2016:16:53-68.

Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study. Clin Endocrinology. 2015;82:136-41.

Anandhasayam A, Arivudainambi T, Kanan S. Prevalence of hypothyroidism and its co-morbidities in relation to the causes and risk factors in patients undergoing levothyroxine therapy. Int J Pharmaceutical Sci Res. 2016;7(3):1251-7.

Paul J, Dasgupta S. Co-morbidities in Hypothyroid Patients in a Tertiary Health Care Hospital in India. J Thyroid Disorders Ther. 2012;1(2):1-4.

Pola GMJ, Pendas SLS, Romero SJM. Thyroid Disease and Oral Lichen Planus as Comorbidity: A Prospective Case-Control Study. Dermatology. 2016;232:214-9.

Lam L, Nair R, Tingle L. Thyrotoxic periodic paralysis. Thyrotoxic periodic paralysis. Proc (Bayl Univ Med Cent). 2006;19:126-9.

Zamfirescu I, Carlson HE. Absorption of Levothyroxine When Co-administered with Various Calcium Formulations. Thyroid. 2011;21(5):483-6.

Mazokopakis E, Giannakopoulos G, Starakis L. Interaction between levothyroxine and calcium carbonate. Canadian Family Physician. 2008;54:39.

Qari F. Hypothyroidism in Clinical Practice. J Family Med Primary Care. 2014;3(2):98-101.

Khanna D, Park G, Paulus H, Simpson K. Reduction of the Efficacy of Methotrexate by the Use of Folic Acid. Arthritis Rheumatism. 2005;52(10):3030-8.

Horacek J, Simko J, Waberzinek G. Carbamazepine and risk of hypothyroidism: a prospective study. Endocrine Abstracts. 2007:318.

Sachmechi I, Reich D, Aninyei M, Wibowo F. Effect of Proton Pump Inhibitors on Serum Thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocrine Practice. 2007;13(4):345-9.




How to Cite

Narwade, S. D., & Barve, R. M. (2020). Assessment of comorbidities in patients with deranged thyroid hormone levels. International Journal of Basic & Clinical Pharmacology, 9(7), 1044–1049.



Original Research Articles